Burning Rock Biotech Limited (BNR)

Market Cap	318.23M
Revenue (ttm)	78.94M
Net Income (ttm)	-139.74M
Shares Out	105.73M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,219
Open	3.04
Previous Close	3.03
Day's Range	2.88 - 3.04
52-Week Range	1.70 - 11.27
Beta	0.07
Analysts	Buy
Price Target	6.95 (+130.9%)
Earnings Date	Mar 20, 2023

About BNR

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian canc...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 1,394
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR

Financial Performance

In 2021, BNR's revenue was 507.86 million, an increase of 18.13% compared to the previous year's 429.90 million. Losses were -796.70 million, 68.8% more than in 2020.

Financial numbers in CNY

Analyst Forecast

According to 8 analysts, the average rating for BNR stock is "Buy." The 12-month stock price forecast is $6.95, which is an increase of 130.90% from the latest price.

Price Target

$6.95

(130.90% upside)

Analyst Consensus: Buy